Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Drug Resistance

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 30 articles:
HTML format
Text format



Single Articles


    March 2017
  1. KANTHULA R, Rossouw T, Feucht UD, Van Dyk G, et al
    Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission.
    AIDS. 2017 Mar 15. doi: 10.1097/QAD.0000000000001446.
    PubMed     Text format     Abstract available


    January 2017
  2. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Text format     Abstract available


    November 2016
  3. KUNKEL A, Crawford FW, Shepherd J, Cohen T, et al
    Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    AIDS. 2016;30:2715-2723.
    PubMed     Text format     Abstract available


    September 2016
  4. MURI L, Gamell A, Ntamatungiro AJ, Glass TR, et al
    Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania - an emerging public health concern.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  5. VILLABONA-ARENAS CJ, Vidal N, Guichet E, Serrano L, et al
    In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    June 2016
  6. OLIVEIRA M, Ibanescu RI, Pham HT, Brenner B, et al
    The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    April 2016
  7. MUSIIME V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, et al
    Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  8. CHUNG MH, Silverman R, Beck IA, Yatich N, et al
    Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    January 2016
  9. CASADELLA M, Noguera-Julian M, Sunpath H, Gordon M, et al
    Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  10. WEIS JF, Baeten JM, McCoy CO, Warth C, et al
    Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    AIDS. 2016;30:31-5.
    PubMed     Text format     Abstract available


  11. VAN LUNZEN J, Antinori A, Cohen CJ, Arribas JR, et al
    Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    AIDS. 2016;30:251-9.
    PubMed     Text format     Abstract available


    November 2015
  12. KONOU AA, Dagnra AY, Vidal N, Salou M, et al
    Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo.
    AIDS. 2015;29:2527-30.
    PubMed     Text format     Abstract available


    September 2015
  13. WINAND R, Theys K, Eusebio M, Aerts J, et al
    Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.
    AIDS. 2015;29:2045-52.
    PubMed     Text format     Abstract available


  14. MOURAD R, Chevennet F, Dunn DT, Fearnhill E, et al
    A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.
    AIDS. 2015;29:1917-25.
    PubMed     Text format     Abstract available


  15. OLIVEIRA M, Mesplede T, Moisi D, Ibanescu RI, et al
    The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    August 2015
  16. PETERSON CW, Haworth KG, Polacino P, Huang ML, et al
    Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.
    AIDS. 2015;29:1597-606.
    PubMed     Text format     Abstract available


    July 2015
  17. LOPES GI, Coelho LP, Hornke L, Volpato AP, et al
    Transmission of a multidrug-resistant HIV-1 from an occupational exposure, in Sao Paulo, Brazil.
    AIDS. 2015;29:1580-3.
    PubMed     Text format    


  18. CASADELLA M, Manzardo C, Noguera-Julian M, Ferrer E, et al
    Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.
    AIDS. 2015;29:1493-504.
    PubMed     Text format     Abstract available


  19. OLSON SC, Ngo-Giang-Huong N, Beck I, Deng W, et al
    Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
    AIDS. 2015;29:1467-71.
    PubMed     Text format     Abstract available


  20. MESPLEDE T, Quashie PK, Hassounah S, Osman N, et al
    The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
    AIDS. 2015;29:1459-66.
    PubMed     Text format     Abstract available


  21. HARPER KN
    New study suggests resistance testing may not be best use of resources for HIV treatment programmes in low-income settings.
    AIDS. 2015;29:N7.
    PubMed     Text format    


  22. NELSON JA, Fokar A, Hudgens MG, Compliment KJ, et al
    Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis: results of the Breastfeeding, Antiretrovirals and Nutrition study.
    AIDS. 2015.
    PubMed     Text format     Abstract available


  23. LIMA VD, Reuter A, Harrigan PR, Lourenco L, et al
    Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    June 2015
  24. ALESSANDRI-GRADT E, Morgand M, Delaugerre C, Peytavin G, et al
    HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    AIDS. 2015;29:1271-3.
    PubMed     Text format    


  25. BONADIES G, Maraolo AE, Tambaro O, Palmiero G, et al
    Dolutegravir: successful experience in a challenging patient.
    AIDS. 2015;29:1269-71.
    PubMed     Text format    


  26. PERE H, Roques P, Talla F, Meillo H, et al
    Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.
    AIDS. 2015;29:1267-9.
    PubMed     Text format    


  27. THIO CL, Smeaton L, Hollabaugh K, Saulynas M, et al
    Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    AIDS. 2015;29:1173-82.
    PubMed     Text format     Abstract available


  28. SCHULTZE A, Phillips AN, Paredes R, Battegay M, et al
    HIV resistance testing and detected drug resistance in Europe.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    May 2015
  29. ABECASIS AB, van Laethem K, Theys K
    Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
    AIDS. 2015;29:987-8.
    PubMed     Text format    


    April 2015
  30. LI JZ, Smith DM, Mellors JW
    The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure.
    AIDS. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: